杭州市上城区钱江新城城星路 69 号中天国开大厦 10/12 层 310020 10&12/F, Zhongtian Guokai Building, 69 Chengxing Road, Qianjiang CBD, Shangcheng District, Hangzhou 310020, China 电话 Tel: +86 571 8829 8760 电邮 Email: hangzhou@tongshang.com 网址 Web: www.tongshang.com 北京通商（杭州）律师事务所 关于英飞特电子（杭州）股份有限公司 致：英飞特电子（杭州）股份有限公司 北京通商（杭州）律师事务所（以下简称"本所"）接受英飞特电子（杭州） 股份有限公司（以下简称"公司"）委托，指派本所律师对公司召开 2025 年第二 次临时股东会（以下简称"本次股东会"）的合法性进行见证并出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的与本次股东会相关的文件 和资料，同时听取了公司人员就有关事实的陈述和说明。本所已得到公司的如下 保证，保证其所提供的文件和资料是真实、准确、完整的，并无隐瞒、虚假和重 大遗漏之 ...

证券代码：300582 证券简称：英飞特 公告编号：2025-069 英飞特电子（杭州）股份有限公司 3、本次股东会采用现场投票和网络投票相结合的表决方式进行； 4、本次股东会对中小投资者进行单独计票。中小投资者是指除单独或合计 持有上市公司5%以上股份的股东以及上市公司的董事、高级管理人员以外的其 他股东。 一、会议召开和出席情况 1、英飞特电子（杭州）股份有限公司（以下简称"公司"）2025年第二次临 时股东会会议通知于2025年11月13日以公告形式发出。 2、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 3、会议召开时间： 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示 1、本次股东会没有出现否决议案的情形； 2、本次股东会没有涉及变更前次股东会决议的情形； 1）现场会议召开时间：2025年11月28日（周五）下午 14:40 2）网络投票时间：2025年11月28日。其中，通过深圳证券交易所（以下简 称"深交所"）交易系统进行网络投票的时间为深圳证券交易所交易时间，即2025 年11月 ...

Core Viewpoint - The company, Infit, primarily engages in the research, production, sales, and technical services of LED lighting supporting products, including LED drivers, sensors, control systems, and LED modules [1] Group 1: Company Overview - Infit focuses on LED lighting products and solutions, indicating a strong presence in the LED market [1] - The company also offers energy storage solutions, specifically targeting commercial and residential sectors, although the current scale of this segment is relatively small [1]

Core Viewpoint - The company, Infinet (300582.SZ), focuses on the research, production, sales, and technical services of LED lighting products, including LED drivers, sensors, control systems, and LED modules [1] Group 1: Company Overview - The main business activities of the company include the development and production of LED lighting supporting products [1] - The company also offers energy storage solutions, primarily targeting commercial and residential sectors, although its current scale in this area is relatively small [1]

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Group 1 - The company Infit (300582.SZ) announced that its wholly-owned subsidiary, Hangzhou Infit Equity Investment Co., Ltd., will invest in Qinghai Spring Warm Flower Biotechnology Co., Ltd. and its existing shareholders through a capital increase and share transfer agreement [1] - The investment includes a cash contribution of 13.44 million yuan to increase the registered capital of Spring Warm Flower by 1.344 million yuan, with the remaining amount recorded as capital surplus [1] - After the transaction, the company will directly hold 2.62% of the equity in the target company and indirectly hold 3.04% through Blincao Biotechnology [1] Group 2 - This transaction allows the company to deepen its application scenarios in plant/biological lighting, accurately understand customer needs, and iteratively improve LED driver power supplies, sensors, and control systems [2] - The strategic shift from a "single hardware supplier" to a "system solution provider" will enhance customer loyalty and technical barriers, maintaining the company's competitive advantage in the plant (biological) lighting segment [2]

Group 1 - The company announced that its wholly-owned subsidiary, Hangzhou Infit Investment Co., Ltd., will invest 13.44 million yuan in Qinghai Spring Warm Flower Biotechnology Co., Ltd. and acquire shares from existing shareholders [1] - After the transaction, the company will directly hold 2.62% of the target company's equity and indirectly hold 3.04% through Blincao Biotechnology [2] - This transaction aims to enhance the application scenarios of plant/biological lighting, allowing the company to better understand customer needs and transition from a "single hardware supplier" to a "system solution provider" [2]

Core Viewpoint - The company Infinitus (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, aiming to invest in Qinghai Chunwarm Biotechnology Co., Ltd. and its existing shareholders [1][2] Group 1: Investment Details - Infinitus plans to invest a total of 13.44 million yuan in cash, which includes a capital increase of 1.344 million yuan and the remainder as capital premium [1] - The company will acquire all registered capital of 1.56 million yuan from Blincao Biotechnology Co., Ltd. for 1.56 million yuan [1] - After the transaction, Infinitus will hold 2.62% direct equity in the target company and an additional 3.04% indirectly through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder and chairman, Guichaohua, has committed to a buyback agreement if the target company's net profit is negative for the years 2026 and 2027, or if the cumulative net profit for 2026, 2027, and 2028 does not reach 60 million yuan [2] - This transaction is classified as a related party transaction due to the buyback commitment [2]

Core Viewpoint - Infinitus (300582) announced an investment through its wholly-owned subsidiary, Hangzhou Infinitus Equity Investment Co., Ltd., to acquire stakes in Qinghai Spring Blossoms Biotechnology Co., Ltd. and Hangzhou Bincao Biotechnology Co., Ltd. [1] Group 1: Investment Details - The company plans to invest 13.44 million yuan in cash to subscribe for an additional registered capital of 1.344 million yuan in Qinghai Spring Blossoms, with the remaining amount recorded as capital surplus [1] - The company will also acquire all registered capital of 1.56 million yuan from Xu Danhong and Gao Minjian in Hangzhou Bincao Biotechnology Co., Ltd. [1] - After the transactions, the company will directly hold 2.62% of Qinghai Spring Blossoms and indirectly hold 3.04% through Bincao Biotechnology [1] Group 2: Technology and Business Focus - Qinghai Spring Blossoms utilizes biotechnology, plant growth lighting, and environmental control technology to standardize the supply of high-value-added raw materials [1] Group 3: Management Commitment - The company's actual controller and chairman, Guichao Hua, will assume a potential buyback obligation for this investment [1]

Core Viewpoint - Infinet (300582.SZ) has approved a capital increase and equity transfer agreement involving its wholly-owned subsidiary, Hangzhou Infinet Equity Investment Co., Ltd., and Qinghai Chunwarm Biotechnology Co., Ltd., indicating a strategic investment move in the biotechnology sector [1] Group 1: Investment Details - Infinet Equity Investment plans to invest CNY 13.44 million in Chunwarm Biotechnology, with CNY 1.344 million allocated to the new registered capital and the remainder as capital premium [1] - The company will also acquire all registered capital of Blincao Biotechnology for CNY 1.56 million, which is part of the overall transaction [1] - Upon completion of the transaction, Infinet Equity Investment will hold 2.62% direct equity in Chunwarm Biotechnology and an indirect 3.04% through Blincao Biotechnology [1] Group 2: Profit Guarantees - The controlling shareholder, GUICHAOHUA, has committed to a profit guarantee, allowing Infinet Equity Investment to demand a buyback of its shares if Chunwarm Biotechnology's net profit is negative over 2026 and 2027, or if the combined net profit for 2026, 2027, and 2028 does not reach CNY 60 million [2] - This transaction is classified as a related party transaction due to the involvement of the controlling shareholder [2]